Last reviewed · How we verify
Multivirus Specific T cells
Multivirus Specific T cells is a Biologic drug developed by AlloVir. It is currently in Phase 1 development.
Multivirus-specific T cells are a type of cell therapy used to treat various viral infections, including adenovirus, Epstein-Barr virus, and cytomegalovirus infections, as well as stem cell transplant complications. This treatment involves the use of somatic cell supplemental therapy, where autologous T cells are expanded ex vivo to express specific marker proteins and then administered to the patient.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Multivirus Specific T cells |
|---|---|
| Sponsor | AlloVir |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation (PHASE1)
- TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT. (PHASE1)
- TETRAVI Expanded Access Program
- Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections (PHASE3)
- Allogeneic Virus-specific T Cell Lines (VSTs) (PHASE1)
- Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (PHASE1, PHASE2)
- Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia (PHASE2)
- Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Multivirus Specific T cells CI brief — competitive landscape report
- Multivirus Specific T cells updates RSS · CI watch RSS
- AlloVir portfolio CI
Frequently asked questions about Multivirus Specific T cells
What is Multivirus Specific T cells?
Who makes Multivirus Specific T cells?
What development phase is Multivirus Specific T cells in?
Related
- Manufacturer: AlloVir — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing